- All
- About MAA News Items
- Annual Conference News Items
- Art With Heart News Items
- Get Involved News Items
- Health Professionals News Items
- Living with MG News Items
- MG Awareness Month News Items
- Patient Tool Kit
- Policy Makers News Items
- Understanding MG News Items
Register now! Multi-stakeholder webinar on Myasthenia research updates
The Myasthenia Alliance Australia is partnering with OPTIMAL NHMRC Centre for Research Excellence in improving immunoglobulin use, and we invite you to join our upcoming webinar on Myasthenia Gravis. Date: Monday 24th November 2025 Time: This session will bring together clinicians, researchers, and people with lived experience to discuss current understanding of Myasthenia Gravis, insights from national research on immunoglobulin…
EXPERT INSIGHTS: Myasthenia Gravis and symptom assessment tools to improve outcomes
How do we truly understand what life is like for someone living with myasthenia gravis? In this insightful webinar, Dr Carlo Antozzi, Senior Neurologist and Head of the Neuroimmunology and Neuromuscular Diseases Unit at the Besta Neurological Institute in Milan, takes us inside the evolving world of MG care – one where patients’ voices are…
NURSING EXCELLENCE and the vital role of nurses in MG care
Myasthenia Alliance Australia (MAA) are delighted to invite you to an informative webinar with Nurse Practitioner Jenny Stofmeel. 🗓️ Tuesday 28th October 2025 ⏰ 5:30pm – 6:30pm AEST Nurse Stofmeel will share valuable insights on managing the day-to-day challenges of rare neurological conditions, and accessing the support you need, as well as the important role…
Another opportunity to share your experience and preferences about treatments – make a PBAC submission for Vyvgart® in subcutaneous injection form
Another opportunity to share your experience and preferences about treatments – make a PBAC submission for Vyvgart® in subcutaneous injection form The Pharmaceutical Benefits Advisory Committee (PBAC) will assess the subcutaneous injection form of Vyvgart® (efgartigimod alfa) for acetylcholine receptor autoantibody positive (AChR+) gMG patients at its meeting in November 2025. Efgartigimod alfa is a…
Congenital Myasthenic Syndrome (CMS) patients – please complete this MAA survey!
The MAA would like to hear from ALL Australians diagnosed with CMS. We need to capture your numbers (parents/guardians can respond on behalf of children). We also want to learn about your experiences here in Australia regarding accessing Ruzurgi/Amifampridine/3,4-DAP as a treatment option. The supplier of Ruzurgi is working towards achieving PBS funding for CMS…
LET’S SHOW OUR APPRECIATION TO DR CARLO ANTOZZI: Don’t miss out on this incredible expert insights event
Myasthenia Alliance Australia is delighted to remind our community of an important upcoming event. 📅 Date: Monday 15 September🕛 Time: 12:30pm – 2:00pm📍 Location: Rydges South Bank, Brisbane With thanks to the generous support of Argenx, we will be welcoming Dr Carlo Antozzi to speak on “Myasthenia Gravis and Symptom Assessment Tools to Improve Outcomes.”…
Why volunteer? Experiencing the MG Patient Advocacy Organisation (PAO) Summit is just one example!
In May this year, people who are both a patient and patient advocate or representative came together in Den Haag, in The Netherlands. We came from about 15 different countries. I had not met one of them before arriving there, and yet I felt immediately at home. Although we come from different countries with different…
- « Previous
- 1
- 2
- 3
- Next »